Point-of-care antigen test earns FDA emergency use authorization
The Food and Drug Administration Monday authorized the emergency use of the BD (Becton Dickinson) Veritor System for Rapid Detection of SARS-CoV-2.
The test is the second antigen diagnostic to earn an emergency use authorization from FDA and can be used in patient care settings approved for CLIA high or moderate complexity or waived testing.
However, the test’s emergency use is limited to authorized laboratories using the BD Veritor Plus Analyzer Instrument.
Related News Articles
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…